Last reviewed · How we verify
Cell-derived influenza vaccine — Competitive Intelligence Brief
marketed
Biologic
Live · refreshed every 30 min
Target snapshot
Cell-derived influenza vaccine (Cell-derived influenza vaccine) — Novartis Vaccines.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Cell-derived influenza vaccine TARGET | Cell-derived influenza vaccine | Novartis Vaccines | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Cell-derived influenza vaccine CI watch — RSS
- Cell-derived influenza vaccine CI watch — Atom
- Cell-derived influenza vaccine CI watch — JSON
- Cell-derived influenza vaccine alone — RSS
Cite this brief
Drug Landscape (2026). Cell-derived influenza vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/cell-derived-influenza-vaccine. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab